Basic Information
| LncRNA/CircRNA Name | FGFR3-AS1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | RT-qPCR, Western blot, in vitro knockdown |
| Sample | bladder cancer tissues, cell lines (T24, 5637, UM-UC-3, SW-780 and SV-HUC-1) |
| Expression Pattern | up-regulated |
| Function Description | Both FGFR3-AS1 and FGFR3 were overexpressed in bladder cancer tissues compared to matched normal tissues. They were also positively expressed in bladder cancer. FGFR3-AS1 expression levels were higher in high grade tumors than those in low grade tumors. FGFR3-AS1 expression levels were higher in invasive tumors than those in non-invasive tumors. Cell proliferation inhibition, increased apoptosis, and decreased motility were observed in FGFR3-AS1 siRNA-transfected T24 and 5637 cell lines.Genomic alterations of FGFR3, such as translocations and activating mutations, have been found in advanced and metastatic urothelialcarcinoma. |
| Pubmed ID | 29226855 |
| Year | 2018 |
| Title | Knockdown of long noncoding RNA FGFR3- AS1 induces cell proliferation inhibition, apoptosis and motility reduction in bladder cancer. |
External Links
| Links for FGFR3-AS1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |